drugset / Trial / NCT06370715
A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India. The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).
Timeline
- Start
- 2024-04-18
- Primary completion
- 2025-09-02
- Completion
- 2025-09-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin Lispro-aabc | Protein / enzyme biologic | — | Subcutaneous |
| Background | insulin glargine | Protein / enzyme biologic | — | Subcutaneous |